Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12096341 | 0.89 | TDP1 (0.52) | ALDH1A1TSHRFGFR4TDP1DPP4 | |
| Acrylamide SCHEMBL29019443 | 0.88 | ALDH1A1 (0.52) | LMNAALDH1A1TSHRFGFR4DPP4 | |
| Acetic Acid SCHEMBL1077081 | 0.87 | ALDH1A1 (0.39) | LMNAALDH1A1TSHRMEN1KMT2A | |
| Acrylamide SCHEMBL27520394 | 0.86 | ALDH1A1 (0.50) | LMNAALDH1A1TSHRFGFR4DPP4 | |
| Acrylamide SCHEMBL8165211 | 0.86 | ALDH1A1 (0.50) | LMNAALDH1A1TSHRFGFR4DPP4 | |
| Butanedione SCHEMBL27468486 | 0.85 | ALDH1A1 (0.38) | LMNAALDH1A1TSHRMEN1KMT2A | |
| Bicarbonate SCHEMBL28060031 | 0.84 | ALDH1A1 (0.41) | LMNAALOX15ALDH1A1TSHRDPP4 | |
| Bicarbonate SCHEMBL28060029 | 0.84 | ALDH1A1 (0.41) | LMNAALOX15ALDH1A1TSHRDPP4 | |
| Hydroxyamine SCHEMBL27886493 | 0.84 | — | — | |
| Glycine SCHEMBL29866 | 0.81 | GLRA1 (0.46) | LMNAALOX15BLMALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367705-A1 | NANOPARTICLES COMPRISED OF SHELLS ASSOCIATED WITH CHARGED ENTITIES AND FORMED FROM MONOMERS AND METHODS OF MAKING AND USING NANOPARTICLES | NEW YORK UNIVERSITY (US) | 2016-12-22 | — | — | US | claimed |
| US-20240051832-A1 | METHODS AND SYSTEMS FOR PRODUCING SOLID INORGANIC CARBONATE AND BICARBONATE COMPOUNDS | CORNELL UNIVERSITY (US) | 2024-02-15 | — | — | US | disclosed |
| EP-4208281-A2 | METHODS AND SYSTEMS FOR PRODUCING SOLID INORGANIC CARBONATE AND BICARBONATE COMPOUNDS | Cornell University (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20160367705-A1 | NANOPARTICLES COMPRISED OF SHELLS ASSOCIATED WITH CHARGED ENTITIES AND FORMED FROM MONOMERS AND METHODS OF MAKING AND USING NANOPARTICLES | NEW YORK UNIVERSITY (US) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367705-A1 | NANOPARTICLES COMPRISED OF SHELLS ASSOCIATED WITH CHARGED ENTITIES AND FORMED FROM MONOMERS AND METHODS OF MAKING AND USING NANOPARTICLES | CHMP4B, RCC1, CD14 | LMNA 145/4885ALOX15 3684/4885BLM 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.